EnVivo Completes Phase Ib/IIa Trial Of EVP-6124
EnVivo has completed phase Ib/IIa trial in Alzheimer’s disease patients with its nicotinic alpha-7 agonist EVP-6124. Subjects receiving EVP-6124 experienced improvement in cognition and EVP-6124 showed good tolerability
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.